First-Ever gene therapy targets brain cells in devastating childhood disease

NCT ID NCT04833907

ENROLLING_BY_INVITATION Disease control Sponsor: Myrtelle Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new, one-time gene therapy for children with Canavan disease, a severe and fatal genetic brain disorder. The therapy is delivered directly into the brain during a surgical procedure, aiming to replace the faulty gene in the specific brain cells that cause the disease. Researchers will check if the treatment is safe and if it can improve brain health and motor skills in up to 24 children.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANAVAN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dayton Children's Hospital

    Dayton, Ohio, 45404, United States

Conditions

Explore the condition pages connected to this study.